The GLP-1 question, answered with the actual evidence.

How the worry started

In 2023, regulators in the United States and Europe began receiving reports of suicidal thoughts in some people taking GLP-1 medicines, the class that includes semaglutide and tirzepatide. Both the FDA and the European Medicines Agency opened formal reviews, and Britain's regulator did the same. The worry was legitimate and it was investigated properly, which matters, because what an investigation finds is worth more than what a news cycle fears.

What two years of investigation found

In January 2026, the FDA announced its conclusion. Its own analysis pooled 91 placebo-controlled trials with 107,910 patients and found no increased risk of suicidal thoughts or behaviors on these medicines, and no increase in anxiety, depression, irritability, or psychosis. A second analysis, using health records for about 2.24 million people, compared GLP-1 users with people on another diabetes medicine class and found no increased risk of intentional self-harm. The FDA then asked the makers of the weight-loss versions to take the suicidal thoughts warning off their labels. Britain's regulator had reached the same conclusion in 2024. The FDA's advice to patients was to keep taking prescribed medicine and to discuss concerns with their clinician, and its advice to clinicians was that anyone who discloses suicidal thoughts should be referred for evaluation, as always.

Why the early reports misled

A single report of a bad event cannot tell you what caused it. The conditions these medicines treat carry their own risk: depression and suicidal thinking are more common in people living with obesity and diabetes, whether or not they take anything for them. When millions of people take a medicine, painful events will sometimes happen near it in time by coincidence alone. The way scientists separate coincidence from cause is the controlled comparison, groups of similar people who did and did not take the medicine, and every well-controlled comparison in this story has come back with the same answer: no increase in risk.

The study that points the other way

One large study went further. Researchers in Sweden followed people with depression and anxiety across the whole country and compared each person with themselves: the same patient, in months on a GLP-1 medicine and months off it. Worsening of depression, anxiety, and self-harm was less common during the months on the medicine. That is genuinely interesting, and it is not proof. A study like this cannot rule out other explanations, and its authors say trials designed for the question are still needed. The honest summary is that the safety question has been answered about as well as it can be, and the benefit question is still open.

What this means in the therapy room

Two practical things. First, tell your therapist and your prescriber what you are taking, including medicines prescribed somewhere else. These medicines slow digestion, which can change how some oral medicines are absorbed, and your prescriber needs the complete list. Second, expect the emotional side of rapid change to be real even when the medicine is safe. Eating is tied to comfort, routine, celebration, and grief, and when appetite and weight shift quickly, feelings follow. That is not a side effect to endure in silence. It is exactly the kind of material therapy is for.

The short version

The largest reviews ever done on this question found no increased risk of depression or suicidal thoughts from GLP-1 medicines. They are not mental health treatments, and nobody should take them for mood. And your own experience still outranks every statistic: if your mood changes after starting any medicine, that is worth a conversation with your clinician, promptly.

Sources

Everything in this article traces back to the sources below. Where a number appears, it is the study's own number.

U.S. Food and Drug Administration, Drug Safety Communication, January 13, 2026: the FDA review of GLP-1 medicines and suicidal thoughts and behaviors, and its request to remove that warning language from the weight-loss labels. Medscape's report of the FDA announcement.

Han and colleagues, Diabetes, Obesity and Metabolism (2026): a systematic review and meta-analysis of 86 randomized trials with 133,378 participants, on GLP-1 medicines and psychiatric disorders. PubMed record.

Swedish national cohort study, The Lancet Psychiatry (2026): GLP-1 use and worsening mental illness in people with depression and anxiety. The Lancet Psychiatry.

Systematic review of psychiatric safety, Cureus (2026): 11 studies covering more than 4.9 million patients. PubMed record.

Please read this part

This article is educational and is not medical advice. It does not create a treatment relationship, and it cannot say what any medicine will do for you personally. If you take a GLP-1 medicine and notice your mood changing, bring it to your prescriber or your therapist rather than deciding alone. If you are having thoughts of harming yourself, use the crisis options below now, and tell a clinician as soon as you can, whatever you believe is causing them.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or see the crisis page.